Chardan lowered the firm’s price target on Notable Labs to $7 from $9 and keeps a Buy rating on the shares after Notable reported FY23 financial results and provided a business update. The firm’s lower target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTBL:
- Smaller Reporting Status for Notable Labs: Navigating Investor Concerns Amidst Scaled-Down Disclosure
- Notable Labs sees cash runway into 4Q24
- Notable Labs reports 2023 EPS ($3.41) vs. ($21.97) last year
- Notable Labs Reports 2023 Financial Results and Provides a Business Update
- Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024